Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Diabetes. Apr 15, 2025; 16(4): 101731
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.101731

Full Size Figure Download Figure

Figure 1 Flowchart on study retrieval and inclusion in the meta-analysis.

Citation: Kamrul-Hasan ABM, Pappachan JM, Dutta D, Nagendra L, Kuchay MS, Kapoor N. Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis. World J Diabetes 2025; 16(4): 101731
URL: https://www.wjgnet.com/1948-9358/full/v16/i4/101731.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i4.101731

Kamrul-Hasan ABM, Pappachan JM, Dutta D, Nagendra L, Kuchay MS, Kapoor N. Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis. World J Diabetes 2025; 16(4): 101731 [PMID: 40236848 DOI: 10.4239/wjd.v16.i4.101731]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.